Liver Transplantation for Hepatocellular Carcinoma: Lessons Learned and Future Directions

Clinics in Liver Disease

Volumn 15, Issue 4, 2011, Pages 717-725

  Levi, David M ^a,b   Nishida, Seigo ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b Florida   (United States)

Author keywords

Adoptive immunotherapy; Bridge therapy; Cirrhosis; Downstaging; Hepatocellular carcinoma; Liver transplant; Natural killer cells; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT;

CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER SURVIVAL; COMORBIDITY; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; REVIEW; TUMOR RECURRENCE;

CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LIVER NEOPLASMS; LIVER TRANSPLANTATION; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 80054928552     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.08.010     Document Type: Review

References (42)

1. Bosch F.X., Ribes J., Diaz M., et al. Primary liver cancer: worldwide incidence and trends. Gastroenterol 2004, 127(5 Suppl 1):S5-S16.
2. El-Serag H.B., Davila J.A., Petersen N.J., et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003, 139:817-823.
3. El-Serag H.B., Mason A.C. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 2000, 160(21):3227-3230.
4. Bugianesi E. Non-alcoholic steatohepatitis and cancer. Clin Liver Dis 2007, 11:191-207.
5. Iwatsuki S., Starzl T.E., Sheahan D.G., et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991, 214:221-229.
6. Bismuth H., Chiche L., Adam R., et al. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 1993, 218:145-151.
7. Ringe B., Wittekind C., Bechstein W.O., et al. The role of liver transplantation in hepatobiliary malignancy: a retrospective analysis of 95 patients with particular regard to tumor stage and recurrence. Ann Surg 1989, 209:88-98.
8. Schwartz M.E., Sung M., Mor E., et al. A multidisciplinary approach to hepatocellular carcinoma in patients with cirrhosis. J Am Coll Surg 1995, 180:596-603.
9. McPeake J.R., O'Grady J.G., Zaman S., et al. Liver transplantation for primary hepatocellular carcinoma: tumor size and number determine outcome. J Hepatol 1993, 18:226-234.
10. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996, 334:693-699.
11. Freeman R.B., Wiesner R.H., Edwards E., et al. Results of the first year of the new liver allocation plan. Liver Transpl 2004, 10:7-15.
12. Sharma P., Balan V., Hernandez J.L., et al. Liver transplantation for hepatocellular carcinoma: the MELD impact. Liver Transpl 2004, 10:36-41.
13. Ioannou G.N., Perkins J.D., Carithers R.L. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterol 2008, 134:1342-1351.
14. Yao F.Y., Bass N.M., Nikolai B., et al. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003, 9:684-692.
15. Levi D.M., Tzakis A.G., Martin P., et al. Liver transplantation for hepatocellular carcinoma in the model for end-stage liver disease era. J Am Coll Surg 2010, 210:727-734.
16. Thuluvath P.J., Maheshwari A., Thuluvath N.P., et al. Survival after liver transplantation for hepatocellular carcinoma in the MELD and pre-MELD eras and the independent impact of the hepatitis C virus. Transplantation 2009, 15:754-762.
17. Yao F.Y., Ferrell L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: expansion of tumor size limits does not adversely impact survival. Hepatology 2001, 33:1394-1403.
18. Duffy J.P., Vardanian A., Benjamin E., et al. Liver transplantation criteria for hepatocellular carcinoma should be expanded. Ann Surg 2007, 246:502-511.
19. Forner A., Vilana R., Ayuso C., et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnosis criteria for hepatocellular carcinoma. Hepatology 2008, 47:97-104.
20. Shah S.A., Tan J.C., McGilvray I.D., et al. Accuracy of staging as a predictor for recurrence after liver transplantation for hepatocellular carcinoma. Transplantation 2006, 81:1633-1639.
21. Farinati F., Marino D., De Giorgio M., et al. Diagnostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?. Am J Gastroenterol 2006, 101:524-532.
22. Vivarelli M., Cuchetti A., La Barba G., et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg 2008, 248:857-862.
23. Yao F.Y., Xiao L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transpl 2007, 7:2587-2596.
24. Yang S.H., Suh K., Lee H.W., et al. A revised scoring system utilizing serum alpha-fetoprotein levels to expand candidates for living donor transplantation in hepatocellular carcinoma. Surgery 2007, 141:598-609.
25. Schwartz M., Roayaie S., Uva P. Treatment of HCC in patients awaiting liver transplantation. Am J Transplant 2007, 7:1875-1881.
26. Rossi S., Ravetta V., Rosa L., et al. Repeated radiofrequency ablation for management of patients with small hepatocellular carcinomas: a long-term cohort study. Hepatology 2011, 53:136-147.
27. Lu D.S.K., Yu N.C., Raman S.S., et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005, 41:1130-1137.
28. Porrett P.M., Peterman H., Rosen H., et al. Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocellular carcinoma in the current MELD era. Liver Transpl 2006, 12:665-673.
29. Lesurtel M., Mullhaupt B., Pestalozzi B.C., et al. Transarterial chemoembolization as a bridge to liver transplantation for hepatocellular carcinoma: an evidence based analysis. Am J Transplant 2006, 6:2644-2650.
30. Belghiti J., Carr B.I., Greig P.D., et al. Treatment before liver transplantation for HCC. Ann Surg Oncol 2008, 15:993-1000.
31. Yao Y.F., Kerlan R.K., Hirose R., et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention to treat analysis. Hepatology 2008, 48:819-827.
32. Forner A., Reig M.E., de Lope C.R., et al. Current strategy for staging and treatment: BCLC update and future prospects. Semin Liver Dis 2010, 30:61-74.
33. Pomfret E.A., Washburn K., Wald C., et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010, 16:62-78.
34. Mazzaferro V., Llovet J.M., Miceli R., et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan Criteria: a retrospective, exploratory analysis. Lancet Oncol 2009, 10:35-43.
35. Avilable at: Accessed August 19, 2011. http://74.43.177.57/courses/2010/sal/abecassis/player.html.
36. Van Gerven M.A.J., Diez F.J., Taal B.G., et al. Selecting treatment strategies with dynamic limited-memory influence diagrams. Artif Intell Med 2007, 40:171-186.
37. Chang T.T., Sawhney R., Monto A., et al. Implementation of a multidisciplinary treatment team for hepatocellular cancer at a Veterans Affairs Medical Center improves survival. HPB 2008, 10:405-411.
38. 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transpl 2009, 9:592-600.
39. 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 2009, 50:682-687.
40. Iizuka N., Oka M., Yamada-Okabe H., et al. Oligonucleotide microarray for prediction of early intrahepatic recurrence of hepatocellular carcinoma after curative resection. Lancet 2003, 361:923-929.
41. Hoshida Y., Villanueva A., Kobayashi M., et al. Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med 2008, 359:1995-2004.
42. Ishiyama K., Ohdan H., Ohira M., et al. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans. Hepatology 2006, 43:362-372.